Ahammune key facts
- Developer of novel drugs designed to treat the early stages of Vitiligo.
- Ahammune’s last known valuation is $24.4M.
- It has raised $7.2M; the latest was Later Stage VC ($5.0M) in Sep 2024.
- Notable investors include Indian Angel Network, Venture Center, Survam Partners, Legacy Assets, Ajith Kamath — 17 tracked in total.
- Status: Privately Held (backing).
Who backs Ahammune
17+Membership and data by Private Market View
- ·The complete investor list: 17 names
- ·Watch Ahammune: the Monday email on marks, rounds and moves
Ahammune funding rounds
No funding rounds for Ahammune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ahammune valuation
Ahammune's last known valuation is $24.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Ahammune investors
17 investors are on record for Ahammune, including Indian Angel Network, Venture Center, Survam Partners and Legacy Assets.
About Ahammune
Developer of novel drugs designed to treat the early stages of Vitiligo. The company's drugs aim to arrest new immune triggers that destroy melanocytes by effector T cells by targeting the activation step of immune cells, and these molecules prevent further killing and spread of depigmentation, enabling medical practitioners to identify cellular pathways and restore them to their homeostatic state using small molecules to maintain skin health.
- Sector
- Healthcare
- HQ
- Pune, India
- Founded
- 2016
- Employees
- 9
- Website
- ahammune.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ahammune’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.